ep beat came street
rais guid vs prior guid
strong renal pharma perform point revenu
inflect lrp
expect fx hurrican
despit ep beat guidanc rang rais modestli
like conservat
oper margin guidanc unchang despit better top-line
pull
littl nervou head print given potenti sell
news despit broad base beat group yet
manag put quarter manag overcom hump
perhap stood us organ revenu trajectori
came bp better vs st model despit face headwind
transderm scop comp residu impact hurrican maria ex
item think organ top-line would come well north
manag also rais oper revenu growth guidanc
bp provid comfort investor set
stage posit legitim mid-singl digit top-line compani
ep guidanc leav room upsid assum
cyclo headwind lesser anticip similar prior year
potenti share repurchas lastli ice cake us
increas guidanc prior bn bn would impli
convers mid seen mani coverag
compani rais ep guidanc remain unchang
contrarian sens provid increment comfort
compani hit bn conclus best-
in-class organ ep compound stori clean b/ rise
interest rate environ caus us reiter outperform
rate rais price target
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
pt impli price-to-earnings blend
pt impli ev/ebitda blend
version sigma spectrum pump way wireless connect drive infus system growth
compon rais ep guid
midpoint rais relat perform broken oper perform
ad mm revenu cyclo guid
contribut also ad guid
brevibloc expect competit
expect expans highest level year littl rel
guidanc continu next page
oper sale growth segment
advanc surgeri excl acquisit cost recothrom preveleak
adjust oper margin expans margin lower vs balanc
adj incom
valuat methodolog base mix discount cash flow analysi rel valuat multipl
increas competit price pressur fluid system fda qualiti issu tax reform uncertainti inabl
articl articl
time dissemin april et
analyst vijay kumar primarili respons prepar research report attest follow view opinion
render research report reflect person view subject compani issuer part research
analyst compens directli relat specif recommend view research report
